Akademik Veri Yönetim Sistemi
8th International Eurasian Conference on Biological and Chemical Sciences (EurasianBioChem 2025), Ankara, Türkiye, 17 - 19 Aralık 2025, ss.151, (Özet Bildiri)
Diabetes mellitus is a chronic disease and many people suffer from this disease. Type 2 diabetes mellitus is the most common type of diabetes, and more than 95% of people with diabetes have type 2 diabetes. Metformin is widely used as an oral hypoglycemic drug in the treatment of type 2 diabetes mellitus. It is a biguanide derived from Galega officinalis and is the first antidiabetic drug used in the treatment of patients with type 2 diabetes mellitus. Some previous reports indicated that MET has antioxidant, anti-inflammatory, antiapoptotic, and anticancer effects. The aim of this study was to determine the potential cytotoxic/anticancer effects of Metformin, which is widely used in the treatment of type 2 diabetes mellitus, on the human breast cancer MCF-7 cell line using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Different concentrations of Metformin (31.25, 62.50, 125, 250, 500, and 1000 µg/mL) were treated with MCF-7 cells at a 24-hour treatment period. A negative control (distilled water) was also maintained in culture. As a result, Metformin statistically significantly reduced cell viability in MCF-7 cells at all concentrations for 24 hours of treatment compared to the control. The half of the inhibitory (IC50) value that kills fifty percent of the cells was found as 1000 µg/mL (% 52.04% cell viability) concentration for 24 h. In conclusion, Metformin exhibited cytotoxic/anticancer effect in MCF-7 cells at between 31.25 µg/mL and 1000 µg/mL concentrations.